**Solid Tumors: Dose Escalation Only (Disease-Specific Expansion)**

- **Advanced solid tumors with positive HER2 expression**
  - Expansion: advanced/metastatic gastroesophageal cancer or colorectal cancer with positive HER2 expression
  - *10358:* Phase 1/1B Study of DS8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)

- **Solid tumors with PTEN or PIK3CB mutations**
  - Expansion: breast, prostate, other solid tumors
  - ▼10131: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

- **Solid tumors, no specific mutations**
  - Expansion: at least one pancreatic cancer cohort and possibly others
  - 10244: Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
  - ▼10070: Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors

- **Solid tumors in patients with known HIV infection**
  - Expansion: metastatic/ recurrent Kaposi sarcoma
  - *10387:* Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 15, 2020